489 related articles for article (PubMed ID: 27438262)
21. Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Wong CR; Nguyen MH; Lim JK
World J Gastroenterol; 2016 Oct; 22(37):8294-8303. PubMed ID: 27729736
[TBL] [Abstract][Full Text] [Related]
22. Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats.
Liu J; Han L; Zhu L; Yu Y
Lipids Health Dis; 2016 Feb; 15():27. PubMed ID: 26868515
[TBL] [Abstract][Full Text] [Related]
23. Protective effect of the Y220C mutant p53 against steatosis: good news?
Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
[TBL] [Abstract][Full Text] [Related]
24. Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease.
Wang B; Yang RN; Zhu YR; Xing JC; Lou XW; He YJ; Ding QL; Zhang MY; Qiu H
Mol Med Rep; 2017 Jan; 15(1):387-395. PubMed ID: 27959408
[TBL] [Abstract][Full Text] [Related]
25. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.
Zhang Y; Chen ML; Zhou Y; Yi L; Gao YX; Ran L; Chen SH; Zhang T; Zhou X; Zou D; Wu B; Wu Y; Chang H; Zhu JD; Zhang QY; Mi MT
Mol Nutr Food Res; 2015 Aug; 59(8):1443-57. PubMed ID: 25943029
[TBL] [Abstract][Full Text] [Related]
27. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21.
Xiao J; Bei Y; Liu J; Dimitrova-Shumkovska J; Kuang D; Zhou Q; Li J; Yang Y; Xiang Y; Wang F; Yang C; Yang W
J Cell Mol Med; 2016 Feb; 20(2):204-16. PubMed ID: 26648452
[TBL] [Abstract][Full Text] [Related]
28. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
Vergani L
Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
[TBL] [Abstract][Full Text] [Related]
30. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
Crespo M; Lappe S; Feldstein AE; Alkhouri N
Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
[TBL] [Abstract][Full Text] [Related]
31. CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.
Chen G; Xu R; Zhang S; Wang Y; Wang P; Edin ML; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2015 Jan; 308(2):E97-E110. PubMed ID: 25389366
[TBL] [Abstract][Full Text] [Related]
32. A human hepatocellular in vitro model to investigate steatosis.
Gómez-Lechón MJ; Donato MT; Martínez-Romero A; Jiménez N; Castell JV; O'Connor JE
Chem Biol Interact; 2007 Jan; 165(2):106-16. PubMed ID: 17188672
[TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
[TBL] [Abstract][Full Text] [Related]
34. In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis.
García-Ruiz I; Solís-Muñoz P; Fernández-Moreira D; Muñoz-Yagüe T; Solís-Herruzo JA
Dis Model Mech; 2015 Feb; 8(2):183-91. PubMed ID: 25540128
[TBL] [Abstract][Full Text] [Related]
35. Autophagy, NAFLD and NAFLD-Related HCC.
Wu WKK; Zhang L; Chan MTV
Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
[TBL] [Abstract][Full Text] [Related]
36. A microfluidic patterned model of non-alcoholic fatty liver disease: applications to disease progression and zonation.
Bulutoglu B; Rey-Bedón C; Kang YBA; Mert S; Yarmush ML; Usta OB
Lab Chip; 2019 Sep; 19(18):3022-3031. PubMed ID: 31465069
[TBL] [Abstract][Full Text] [Related]
37. Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Ganji SH; Kashyap ML; Kamanna VS
Metabolism; 2015 Sep; 64(9):982-90. PubMed ID: 26024755
[TBL] [Abstract][Full Text] [Related]
38. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
39. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells.
Suurmond CE; Lasli S; van den Dolder FW; Ung A; Kim HJ; Bandaru P; Lee K; Cho HJ; Ahadian S; Ashammakhi N; Dokmeci MR; Lee J; Khademhosseini A
Adv Healthc Mater; 2019 Dec; 8(24):e1901379. PubMed ID: 31746151
[TBL] [Abstract][Full Text] [Related]
40. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease.
Gentric G; Maillet V; Paradis V; Couton D; L'Hermitte A; Panasyuk G; Fromenty B; Celton-Morizur S; Desdouets C
J Clin Invest; 2015 Mar; 125(3):981-92. PubMed ID: 25621497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
